Key result
The endoaortic occlusion device (Intraclude) was effectively used in three complex clinical scenarios to minimize operative morbidity during primary and reoperative cardiac surgeries.
Why the study?
Heart Teams increasingly face decision-making in anatomically and clinically complex surgical candidates requiring management with less invasive strategies.
Does the use of an endoaortic occlusion device minimize operative morbidity in complex and reoperative cardiac cases?
Case Report (n=3)
Does the use of an endoaortic occlusion device minimize operative morbidity in complex and reoperative cardiac cases?
The endoaortic occlusion device offers a versatile, less invasive strategy to minimize operative morbidity in complex and reoperative cardiac surgeries.
May aid complex cardiac reoperations; hypothesis-generating and requires prospective validation before wider use.
Heart Teams are increasingly confronted with decision-making in anatomically and clinically complex surgical candidates. Herein, we discuss the versatility of the endoaortic occlusion device (Intraclude; Edwards Lifesciences Inc) for the management of a various array of complex primary and reoperative cardiac cases. Three clinical scenarios are illustrated (ascending aortic pseudoaneurysm, mitral valve surgery after previous CABG, extensive thoracic aortic surgery with continuous visceral perfusion), suggesting the effectiveness of the patient-specific strategy to minimize operative morbidity. Evolution of surgical techniques needs to be considered in decision-making among alternative treatment strategies.
No takes yet. Share an insight, caveat, or question.
Agnino et al. (2019) conducted a case report in Complex primary and reoperative cardiac cases (n=3). Endoaortic occlusion device (Intraclude) was evaluated. The endoaortic occlusion device (Intraclude) was effectively used in three complex clinical scenarios to minimize operative morbidity during primary and reoperative cardiac surgeries.